Jeffrey Binder

analysisBinder was president and chief executive of Biomet from February 2007, and in 2017, as a TPG adviser, took part in TPG's first meetings with the Petty family. ^{1 2 3}

analysisHe was co-executive chairman, then executive chairman, of Exactech and Osteon Holdings from February 2018 to about September 2023 and chief executive from March 2022 to March 2023, and the company's August 2024 Florida report listed him as chairman. ^{1 2 3 4}

qualification

The dates come from the Settlement Trust's complaint; the earlier SEC proxy confirms David Petty as chief executive from March 2014 and president from November 2007, and the Florida and UK registers confirm Johnson as president and chief executive.

analysisThe trust alleges that he has been a TPG senior adviser since 2015, that TPG rather than Exactech paid him more than $1 million for his Exactech work in 2018 and 2019, and that TPG paid him a $1 million success fee for the acquisition. ^{1 2}

qualification

These are allegations in the Settlement Trust's complaint, which was pending in the Delaware Court of Chancery in October 2026; no court has ruled on them. The agreement and payments are described only in the complaint. These are allegations in the Settlement Trust's complaint, which was pending in the Delaware Court of Chancery in October 2026; no court has ruled on them. The deposition, invoice and inspection documents are under seal or were not retrieved.

analysisThe trust alleges that from August 2021 he and John Schilling took charge of the recall response and dealings with the FDA, and that he pressed the FDA not to recall the entire GXL inventory. ^{1 2}

qualification

These are allegations in the Settlement Trust's complaint, which was pending in the Delaware Court of Chancery in October 2026; no court has ruled on them.

response

Binder told a national newspaper in May 2025 that Exactech's investigation of product complaints led it to discover in 2021 a packaging non-conformity that had gone undetected since 2008, many years before TPG's ownership and his tenure, and that when it was discovered Exactech reported it to the FDA in a timely fashion and initiated a recall. TPG told the same newspaper that the packaging issues predated its ownership, that it learned of them only in 2021 and that it 'supported the company as it immediately launched an investigation, initiated a voluntary recall, and provided support programs for physicians and patients'.

analysisHe is a defendant in the Settlement Trust's suit for breach of fiduciary duty as a director or officer of Exactech or Osteon Holdings. ^{1 2 3 4 5}

qualification

These are allegations in the Settlement Trust's complaint, which was pending in the Delaware Court of Chancery in October 2026; no court has ruled on them.

response

TPG has denied wrongdoing, a local television investigation reported in September 2026; in a statement to a national newspaper in May 2025 TPG called it 'categorically false' that it had any prior knowledge of the packaging nonconformance, and in court filings TPG and its affiliates have said that Exactech and TPG maintained 'clearly separate businesses'.

outcome

Pending: the docket showed the case as active on 16 October 2026; a filing of 14 August 2026 attached the Maryland qui tam papers and the plan confirmation order as exhibits, but the filing itself is not in the record and no ruling is recorded.